AKT1 and prostate carcinoma: Ligand-stimulated EphA2 inhibits Akt in PTEN-deficient prostate cancer cells, glioma cells30, and other cell types31,32 and the activation of mTOR/Akt signaling pathway could protect hepatocytes from hepatic IR injury33, suggesting the potential regulating function of Epha2 in hepatic I/R injury.